Knee radiosynovectomy with 153Sm‑hydroxyapatite compared to 90Y‑hydroxyapatite
Carregando...
Data
Data de publicação
Orientador
Título da Revista
ISSN da Revista
Título do Volume
É parte de
É parte de
É parte de
Annals of Nuclear Medicine
Exportar
Resumo
Introduction Radiosynovectomy (RS) with 90Y-hydroxyapatite (90Y-HyA) aims to control knee hemarthrosis in hemophiliac
patients to prevent secondary arthropathy. However, knee RS using 153Sm-hydroxyapatite (153Sm-HyA) is considered less
suitable due to the lower average soft tissue range and energy of 153Sm for large joints, such as the knees.
Purpose The objective of this investigation was to assess the efficacy and safety of knee RS with 153Sm-HyA, compared to
90Y-HyA.
Methods Forty patients were prospectively assigned to undergo knee RS with 153Sm-HyA (n = 19) or with 90Y-HyA (n = 21).
The frequency of hemarthrosis episodes before and after treatment were compared.
Results After six months of knee RS, 153Sm-HyA and 90Y-HyA promoted a similar reduction of hemarthrosis episodes
(50% and 66.7%, respectively). However, after 12 months of knee RS, the reduction of hemarthrosis episodes was significantly
(p = 0.037) higher using 153Sm-HyA (87.5%) compared to 90Y-HyA (50.0%). This discrepancy was more pronounced
(p = 0.002) for 153Sm-HyA compared to 90Y-HyA in adults/adolescents.
Conclusion Knee radiosynovectomy with 153Sm-HyA is safe, reduces hemarthrosis episodes after 12 months of treatments,
especially in adults/adolescents and even with grades III/IV arthropathy, similar to 90Y-HyA. 90Y-HyA seems to promote
better hemarthrosis control in small children.
Como referenciar
SANTOS, ALLAN O.; RICCIARDI, JANAINA B.S.; PAGNANO, RODRIGO; PEREIRA, LUIS F.M.; SAKUMA, EMERSON T.; MATSUDA, MARGARETH M.N.; BERNARDES, EMERSON S.; ARAUJO, ELAINE B.; BRUNETTO, SERGIO Q.; TAKAHASHI, MARIA E.S.; BRUNETTO, EDNA M.; ZULLI, ROBERTO; OZELO, MARGARETH C.; ETCHEBEHERE, ELBA C.S.C. Knee radiosynovectomy with 153Sm‑hydroxyapatite compared to 90Y‑hydroxyapatite: initial results of a prospective trial. Annals of Nuclear Medicine, v. 35, n. 2, p. 232-240, 2021. DOI: 10.1007/s12149-020-01557-5. Disponível em: http://repositorio.ipen.br/handle/123456789/31983. Acesso em: 27 Mar 2026.
Esta referência é gerada automaticamente de acordo com as normas do estilo IPEN/SP (ABNT NBR 6023) e recomenda-se uma verificação final e ajustes caso necessário.